Follow-up LDCT screening for lung cancer decreases recall rates.
The early recall rate for suspicious findings from lung cancer screening significantly decreased with the second and subsequent low-dose multislice CT (MSCT) screening, according to a study published in the Journal of Thoracic Oncology.
Researchers from Germany sought to determine recall rates associated with follow-up (two to four) LDCT screenings for lung cancer. They analyzed the basic characteristics for the annual rounds and the first three years with complete follow-up since time of randomization.
Data were obtained from the German Lung Cancer Screening Intervention Trial (LUSI) after the fourth screening round and three-year follow-up was completed. The researchers looked at early recall rate, detection rate, interval cancers, and the proportion of advanced cancers. A total of 2,035 subjects who received no intervention were compared with 2,029 subjects, aged 50 to 69, with a history of heavy tobacco smoking, who underwent five annual screens.
In reporting the results, the authors wrote, “Early recall rates were significantly lower in the subsequent screening rounds than in the first one if the MSCT information from the previous screening rounds was available. Detection and biopsy rates were around 1 percent or lower, ratio of malignant:benign biopsies 1:1.6-1:3.”
There was a decline in the early recall rate from 20% in the first screening round to 3% to 4% in rounds 2 to 4. Lung cancer detection was 1.1% in the first round, and dropped to an average of 0.5% for the subsequent rounds.
After an almost identical cumulative number of advanced lung cancers and overall mortality among both groups in the first two years, the number of advanced cancers in the screening group began to decline in the third year.
“Our recent data may settle one concern regarding high recall rates in routine MSCT screening, but also indicate that screening must be strictly organized in order to be effective,” the authors concluded. “Performance indicators are similar to those in mammography screening. Nevertheless, possible consequences for the participants (diagnostic workup of suspicious findings, biopsies) are more invasive than in mammography screening.”
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AMA Approves Category III CPT Codes for AI-Enabled Perivascular Fat Analysis from CT Scans
April 9th 2025Going into effect in 2026, the new CPT codes may facilitate increased adoption of the CaRi-Heart software for detecting coronary inflammation from computed tomography scans pending FDA clearance of the technology.
FDA Clears AI Assessment of Ischemic Core Volume on CT with Brainomix 360 Platform
April 8th 2025For patients with acute ischemic stroke, research has demonstrated that automated assessment of ischemic core volume on brain CT scans via the Brainomix 360 software is equivalent to that derived from CT perfusion.